Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dejaco, C; Duftner, C; Klotz, W; Schirmer, M; Herold, M.
Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-alpha treatment response in rheumatoid arthritis.
Rheumatol Int. 2010; 30(4):451-454
Doi: 10.1007/s00296-009-0978-4
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Dejaco Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective of this study is to retrospectively compare the third generation anti-cyclic citrullinated peptide (anti-CCP3) test with the second generation (anti-CCP2) assay as markers of disease activity and predictors of clinical response in rheumatoid arthritis (RA) patients treated with TNF-alpha blocking agents. This study was performed in 42 RA patients treated either with infliximab (n = 11), etanercept (n = 7) or adalimumab (n = 24). Serum anti-CCP3 and anti-CCP2 levels were tested before and 6 months after starting a TNF-alpha blocking treatment using commercially available ELISA kits. Anti-CCP3 and anti-CCP2 antibody levels did not significantly change after 6 months of TNF-alpha blocking treatment. Furthermore, neither anti-CCP3 nor anti-CCP2 was useful to predict anti-TNF-alpha treatment response using receiving operating characteristic curve and logistic regression analyses. Both anti-CCP3 and anti-CCP2 are not differentially influenced by TNF-alpha blocking agents in RA patients and failed to predict anti-TNF-alpha treatment response.
- Find related publications in this database (using NLM MeSH Indexing)
- Antibodies, Anti-Idiotypic - blood
- Antibodies, Monoclonal - therapeutic use
- Antibodies, Monoclonal, Humanized -
- Antirheumatic Agents - therapeutic use
- Arthritis, Rheumatoid - drug therapy
- Autoantibodies - blood
- Disease Progression -
- Female -
- Humans -
- Immunoglobulin G - therapeutic use
- Male -
- Middle Aged -
- Peptides, Cyclic - blood
- Predictive Value of Tests -
- Receptors, Tumor Necrosis Factor - therapeutic use
- Retrospective Studies -
- Treatment Outcome -
- Tumor Necrosis Factor-alpha - antagonists and inhibitors
- Find related publications in this database (Keywords)
- Rheumatoid arthritis
- Autoantibodies
- Tumour necrosis factor-alpha inhibitors
- Cyclic citrullinated peptide